Ampicillin (AURO Ampicillin, Auro-ampicillin, Ropen, Nolix, Trycosil)
Ampicillin
Aurogen South Africa (Pty) Ltd
Registration
- Applicant
- Aurogen South Africa (Pty) Ltd
- Registrations
- 11
- Schedule source
- Consolidated Schedules 06 July 2026
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| AURO ampicillin injection 500 MG EACH VIAL CONTAINS AMPICILLIN SODIUM EQUIVALENT TO AMPICILLIN 500,0 mg | 500 mgInjection | 41012241/20.1.2/0122 | Registered | S4 | None |
| Auro-ampicillin injection 1000 MG EACH VIAL CONTAINS AMPICILLIN SODIUM EQUIVALENT TO AMPICILLIN 1000,0 mg | 1000 mgInjection | 41012341/20.1.2/0123 | Cancelled | S4 | None |
| Ropen 250 MG EACH VIAL CONTAINS AMPICILLIN SODIUM EQUIVALENT TO AMPICILLIN 250,0 mg | 250 mg | 42078342/20.1.2/0783 | Cancelled | S4 | None |
| Ropen 500 MG EACH VIAL CONTAINS AMPICILLIN SODIUM EQUIVALENT TO AMPICILLIN 500,0 mg | 500 mg | 42078442/20.1.2/0784 | Registered | S4 | None |
| Ropen 1 g EACH VIAL CONTAINS AMPICILLIN SODIUM EQUIVALENT TO AMPICILLIN 1,0 g | 1 g | 42078542/20.1.2/0785 | Cancelled | S4 | None |
| Nolix 250 MG injection EACH VIAL CONTAINS AMPICILLIN SODIUM EQUIVALENT TO AMPICILLIN 250,0 mg | 250 mgInjection | 45078245/20.1.2/0782 | Cancelled | S4 | None |
| Nolix 500 MG injection EACH VIAL CONTAINS AMPICILLIN SODIUM EQUIVALENT TO AMPICILLIN 500,0 mg | 500 mgInjection | 45078345/20.1.2/0783 | Cancelled | S4 | None |
| Nolix 1 g injection EACH VIAL CONTAINS AMPICILLIN SODIUM EQUIVALENT TO AMPICILLIN 1000,0 mg | 1 gInjection | 45078445/20.1.2/0784 | Cancelled | S4 | None |
| Trycosil 250 MG injection EACH VIAL CONTAINS AMPICILLIN SODIUM EQUIVALENT TO AMPICILLIN 250,0 mg | 250 mgInjection | 45078545/20.1.2/0785 | Cancelled | S4 | None |
| Trycosil 500 MG injection EACH VIAL CONTAINS AMPICILLIN SODIUM EQUIVALENT TO AMPICILLIN 500,0 mg | 500 mgInjection | 45078645/20.1.2/0786 | Cancelled | S4 | None |
| Trycosil 1 g injection EACH VIAL CONTAINS AMPICILLIN SODIUM EQUIVALENT TO AMPICILLIN 1000,0 mg | 1 gInjection | 45078745/20.1.2/0787 | Cancelled | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Ampicillin sodium equivalent to ampicillin
S4: Ampicillin
- except when listed elsewhere in the Schedules and except intra-mammary preparations thereof, containing tracer dye(s) and intended for the treatment of mastitis in cattle and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947. (Act 36 of 1947)
Consolidated Schedules 06 July 2026, lines 5240 to 5242
Pharmacological class: Penicillins. (class 20.1.2)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(2S,5R,6R)-6-[[(2R)-2-Amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Drag to rotate. Structure from PubChem CID 6249.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.